Can Octreotide Be Added to Parenteral Nutrition Solutions? Point—Counterpoint

1. Lamberts SWJ , van der Lely AJ , de Herder WW, et al. Octreotide. N Engl J Med 1996;334:246–54.

2. Harris AG . Octreotide in the treatment of disorders of the gastrointestinal tract. Drug Invest 1992;4:1–54.

3. Martineau P , Shwed JA , Denis R. Is octreotide a new hope for enterocutaneous and external pancreatic fistulas closure? Am J Surg 1996;172:386–95.

4. Sancho JJ , di Costanzo J , Nubiola P, et al. Randomized double-blind placebo-controlled trial of early octreotide in patients with postoperative enterocutaneous fistula. Br J Surg 1995;82:638–41.

5. Nubiola-Calonge , Sancho J , Segura M, et al. Blind evaluation of the effect of octreotide (SMS 201–995), a somatostatin analogue, on small-bowel fistula output. Lancet 1987;ii:672–3.

6. Scott NA , Finnegan S , Irving MH . Octreotide and postoperative enterocutaneous fistulae: A controlled prospective study. Acta Gastroenterologica Belgica 1993;56:266–70.

7. Torres AJ , Landa JI , Moreno-Azcoita M, et al. Somatostatin in the management of gastrointestinal fistulas: A multicenter trial. Arch Surg 1992;127:97–100.

8. Ippoliti C , Champlin R , Bugazia N, et al. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. J Clin Oncol 1997;15:3350–4.

9. Morton AJP , Durrant STS . Efficacy of octreotide in controlling refractory diarrhea following bone marrow transplantation. Clin Transplant 1995;9:205–8.

10. Ely P , Dunitz J , Rogosheske J, et al. Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease. Am J Med 1991;90:707–10.

11. O'Keefe SJD , Peterson ME , Fleming CR . Octreotide as an adjunct to home parenteral nutrition in the management of permanent end-jejunostomy syndrome. JPEN 1994;18:26–36.

12. O'Keefe SJD , Haymond MW , Bennet WM, et al. Long-acting somatostatin analogue therapy and protein metabolism in patients with jejunostomies. Gastroenterology 1994;107:379–88.

13. Ritchie DJ , Holstad SG , Westrich TJ, et al. Activity of octreotide acetate in a total nutrient admixture. Am J Hosp Pharm 1991;48:2172–5.

14. Hsu VD , Rosen GH , Leslie J. In vitro evaluation of stability of octreotide and compatibility of insulin in parenteral nutrient mixtures [Abstr]. American Society of Hospital Pharmacists Annual Meeting 1991;48:33E.

1. Ritchie DJ , Holstad SG , Westrich TJ, et al. Activity of octreotide acetate in a total nutrient admixture. Am J Hosp Pharm 1991;48:2172–5.

2. Sandoz Pharmaceutical Corporation . Sandostatin package insert. East Hanover, NJ: Sandoz Pharmaceutical Corporation, January, 1997.

3. Trissel LA , Gilbert DL , Martinez JF, et al. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health Syst Pharm 1997;54:1295–300.

4. Clinical Pharmacokinetics. 1993;25:375–91.